February 27, 2017 -Bacteria are getting tougher, but no truly novel antibiotics have made it to market in 30 years
Three of the most fearsome bacteria in the world are Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae. This is because these bacteria have developed resistance to key antibiotic drugs since the more an antibiotic
… Read MoreFebruary 24, 2017 -Challenges and future outlook in the management of the diabetic foot
The MolecuLight i:X was recently featured in a timely invited review article discussing the current challenges and future outlook in the management of diabetic foot. As many of us know, diabetic foot ulcers, are a serious health problem in
… Read MoreJanuary 16, 2017 -This case is another sign that researchers and governments need to take antibiotic resistance seriously.
Public health officials from Nevada are reporting on a case of a woman who died in Reno in September from an incurable infection caused by Klebsiella pneumoniae bacteria. Testing showed the superbug that had spread
… Read MoreDecember 23, 2016 -
Keeping up with their tradition, MolecuLight Inc. participated as a secret Santa in the Adopt-a-Senior 2016 program through LOFT Community Services. This charity provides attention to seniors who deal with loneliness and uncertainty at this special time of the year.
MolecuLight Inc. would like to wish everyone a happy and healthy
… Read MoreNovember 3, 2016 -22nd Annual CAWC Conference in Niagara Falls
The MolecuLight i:X Imaging Device was highly represented in the Oral Poster Presentations Infection Session at the 22nd Annual CAWC Conference in Niagara Falls.
Over 600 registrants and 230 Industry Personnel attended the CAWC Conference, November 3-6 in Niagara Falls.
As a corporate sponsor,
… Read MoreSeptember 16, 2016 -The MolecuLight i:X Imaging Device can instantly visualize potentially harmful bacteria at the point of care
TORONTO – September 16, 2016 – MolecuLight Inc. has received CE Mark approval authorizing commercial sales in the European Union of its MolecuLight i:X Imaging Device, that is revolutionizing wound care.
The MolecuLight i:X will be making
… Read MoreAugust 23, 2016 -Reviewing medical imaging in wound care
There’s no doubt that while medical imaging is standard and routine in most medical fields (e.g. cardiology, oncology, gynecology, etc.), it is far behind in the field of wound care. The recent editorial in Advances in Wound Care highlights the key points of four
… Read MoreJune 23, 2016 -MolecuLight proudly exhibited for the first time at the 2016 WOCN Society & CAET Joint Conference in Montreal, Quebec
The event was organized by The Wound, Ostomy and Continence Nurses SocietyTM (WOCN®) – recognized worldwide for the promotion of safe and effective wound, ostomy and continence (WOC) care – and
… Read MoreJune 21, 2016 -This premier awards program for the medtech industry announced the 2016 winners
Toronto, June 21, 2016: The Medical Design Excellence Awards (MDEA), the premier awards program for the medtech industry announced the 2016 winners on Tuesday, June 14th at a special ceremony at the MD&M East conference and exposition in
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.